Menu
Back to Journals » Biologics: Targets and Therapy » Volume 10
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (491)
- Volume 17, 2023 (12)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 10, 2016
Centrosome – a promising anti-cancer target
Rivera-Rivera Y, Saavedra HI
Biologics: Targets and Therapy 2016, 10:167-176
Published Date: 13 December 2016
Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimiliars
Perrone V, Saragoni S, Buda S, Broccoli A, Degli Esposti L
Biologics: Targets and Therapy 2016, 10:157-165
Published Date: 1 December 2016
Update on sepsis-associated acute kidney injury: emerging targeted therapies
Doyle JF, Forni LG
Biologics: Targets and Therapy 2016, 10:149-156
Published Date: 7 November 2016
Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma
Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J
Biologics: Targets and Therapy 2016, 10:139-148
Published Date: 20 September 2016
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
Cohan S
Biologics: Targets and Therapy 2016, 10:119-138
Published Date: 12 September 2016
New targeted treatments for non-small-cell lung cancer – role of nivolumab
Zago G, Muller M, van den Heuvel M, Baas P
Biologics: Targets and Therapy 2016, 10:103-117
Published Date: 1 August 2016
Neutralizing activities of human immunoglobulin derived from donors in Japan against mosquito-borne flaviviruses, Japanese encephalitis virus, West Nile virus, and dengue virus
Yunoki M, Kurosu T, Koketsu RK, Takahashi K, Okuno Y, Ikuta K
Biologics: Targets and Therapy 2016, 10:99-102
Published Date: 7 July 2016
Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma
Shi J, Guo BY, Zhang Y, Hui Q, Chang P, Tao K
Biologics: Targets and Therapy 2016, 10:89-98
Published Date: 5 July 2016
Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
Myers SP, Mulder AM, Baker DG, Robinson SR, Rolfe MI, Brooks L, Fitton JH
Biologics: Targets and Therapy 2016, 10:81-88
Published Date: 26 May 2016
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S
Biologics: Targets and Therapy 2016, 10:75-80
Published Date: 4 April 2016
Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers
Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K
Biologics: Targets and Therapy 2016, 10:67-73
Published Date: 1 April 2016
Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years
Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG
Biologics: Targets and Therapy 2016, 10:59-66
Published Date: 22 March 2016
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab
Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F
Biologics: Targets and Therapy 2016, 10:53-58
Published Date: 11 March 2016
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab
Petkau JM, Eksteen B
Biologics: Targets and Therapy 2016, 10:33-52
Published Date: 9 March 2016
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Emole J, Talabi T, Pinilla-Ibarz J
Biologics: Targets and Therapy 2016, 10:23-31
Published Date: 26 February 2016
Biosimilars in the management of neutropenia: focus on filgrastim
Caselli D, Cesaro S, Aricò M
Biologics: Targets and Therapy 2016, 10:17-22
Published Date: 18 February 2016
Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Koff JL, Lonial S
Biologics: Targets and Therapy 2016, 10:9-15
Published Date: 25 January 2016
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P
Biologics: Targets and Therapy 2016, 10:1-8
Published Date: 22 January 2016